Kymera Therapeutics, Inc. (KYMR) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $78.14: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 3.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Below-average business quality; Negative price momentum.
Kymera Therapeutics is a clinical-stage biopharmaceutical company using targeted protein degradation (TPD) to develop oral medicines for immune-inflammatory diseases. Its lead programs target STAT6 (KT-621, Phase 2b in atopic dermatitis and asthma), IRF5 (KT-579, Phase 1), and... Read more
Sell if holding. Engine safety override at $78.14: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 3.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.7/10, moderate confidence.
Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 83d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — Kymera Therapeutics, Inc.
Latest news
- Kymera Therapeutics Announces Presentations On Results From KT-621 Clinical Trial At Annual Meetings May 13-16 — benzinga May 15, 2026 positive
- Canaccord Genuity Initiates Coverage On Kymera Therapeutics with Buy Rating, Announces Price Target of $106 — benzinga May 6, 2026 positive
- Kymera Therapeutics Presented New Preclinical Data For KT-579 Demonstrating Disease-modifying Activity In An Inflammator — benzinga May 5, 2026 positive
- Kymera Therapeutics Q1 EPS $(0.71) Beats $(0.88) Estimate, Sales $34.365M Beat $8.614M Estimate — benzinga Apr 30, 2026 positive
- Earnings Scheduled For April 30, 2026 — benzinga Apr 30, 2026 neutral
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-02-26Item 1.01LOWKymera entered at-the-market Sales Agreement with TD Cowen for up to $500M common stock offering. TD Cowen receives up to 3.0% commission. Company not obligated to sell; program active on Nasdaq.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers·2 ceiling hits
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Risk profile below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $78.14: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 3.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $74.56. Score 5.7/10, moderate confidence.
Take-profit target: $106.45 (+36.2% upside). Prior stop was $74.56. Stop-loss: $74.56.
Quality below floor (1.6 < 4.0).
Kymera Therapeutics, Inc. trades at a P/E of N/A (forward -18.2). TrendMatrix value score: 9.0/10. Verdict: Sell.
29 analysts cover KYMR with a consensus score of 4.3/5. Average price target: $118.
What does Kymera Therapeutics, Inc. do?Kymera Therapeutics is a clinical-stage biopharmaceutical company using targeted protein degradation (TPD) to develop...
Kymera Therapeutics is a clinical-stage biopharmaceutical company using targeted protein degradation (TPD) to develop oral medicines for immune-inflammatory diseases. Its lead programs target STAT6 (KT-621, Phase 2b in atopic dermatitis and asthma), IRF5 (KT-579, Phase 1), and IRAK4 (KT-485 via Sanofi collaboration). The company has no product revenue and had $1.6B cash as of Dec 31, 2025.